Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
This study is currently recruiting patients.
| Sponsored by: | Centre Oscar Lambret |
| Information provided: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00541073 |
Purpose:
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and vitamin B12 may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying how well giving pemetrexed together with cisplatin and vitamin B12 works in treating patients with mesothelioma of the chest that cannot be removed by surgery.
| Condition | Intervention | Phase |
|
Malignant Mesothelioma |
Dietary Supplement: vitamin B12 Drug: cisplatin Drug: pemetrexed disodium Genetic: gene expression analysis Other: laboratory biomarker analysis Other: pharmacological study |
Phase 2 |
Eligibility
Study Design: Allocation: Non-Randomized, Primary Purpose: Treatment
Official Title: Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma
Enrollment Size: Both
Gender: 18 Years
Min. Age: N/A
Max. Age: No
Location and Contact Information
, 59020
Centre Oscar Lambret, Lille, 59020, France,
Status: Recruiting
Amelie Lansiaux, MD, PhD 33-32-029-5953
Last modified: July 29 2010.
